Bortezomib-Cyclophosphamide-Dexamethasone (VCD) versus Bortezomib-Thalidomide-Dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis.
Leiba M et al. Br J Haematol. 2014 May 26. doi: 10.1111/bjh.12946. [Epub ahead of print].
Bortezomib-based induction therapy followed by intravenous busulfan-melphalan as conditioning regimen for newly diagnosed myeloma multiple patients.
Blanes M et al. Leuk Lymphoma. 2014 May 14:1-17. [Epub ahead of print].
Comparison of outcomes after autologous stem cell transplantation between myeloma patients with skeletal and soft tissue plasmacytoma.
Shin HJ et al. Eur J Haematol. 2014 May 9. doi: 10.1111/ejh.12377. [Epub ahead of print].
Complete response after autologous stem cell transplant in multiple myeloma.
Kumar L et al. Cancer Med. 2014 Apr 29. doi: 10.1002/cam4.257. [Epub ahead of print].
Safe and effective use of outpatient non-myeloablative allogeneic stem cell transplantation for myeloma.
Campbell P et al. Blood Cancer J. 2014 May 9;4:e213. doi: 10.1038/bcj.2014.33.
Case-adjusted bortezomib-based strategy in routine therapy of relapsed/refractory multiple myeloma shown to be highly effective-A report by Polish Myeloma Study Group.
Walter-Croneck A et al. Leuk Res. 2014 May 4. pii: S0145-2126(14)00122-2. doi: 10.1016/j.leukres.2014.04.011. [Epub ahead of print].